🟢 Aquestive Therapeutics is trading 13.96% up today after Anaphylm studies cleared a key FDA hurdle

Aquestive Therapeutics is trading 13.96% up now at $4.49 after Anaphylm’s usability and drug-absorption studies cleared a key FDA hurdle, strengthening the product’s path toward regulatory resubmission and potential approval.

• Scheduled to report second-quarter 2026 results and provide a business update after market close on August 11, 2026.
• The move is company-specific despite slightly weaker major U.S. indices.